Kintara Therapeutics Inc
NASDAQ:KTRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kintara Therapeutics Inc
NASDAQ:KTRA
|
US |
|
Anadolu Efes Biracilik ve Malt Sanayii AS
OTC:AEBZY
|
TR |
|
Pexip Holding ASA
OSE:PEXIP
|
NO |
|
ABC Arbitrage SA
OTC:ABCCF
|
FR |
|
N
|
Nova Pacific Metals Corp
CNSX:NVPC
|
CA |
|
P
|
Pricer AB
STO:PRIC B
|
SE |
|
Broken Hill Mines Ltd
ASX:BHM
|
AU |
|
T
|
TPC Consolidated Ltd
ASX:TPC
|
AU |
|
G
|
GeoPark Ltd
NYSE:GPRK
|
CO |
|
G
|
Great Rich Technologies Ltd
KOSDAQ:900290
|
HK |
|
Baytex Energy Corp
TSX:BTE
|
CA |
|
IDT Corp
NYSE:IDT
|
US |
|
R
|
Royal Orchid Hotel Thailand PCL
SET:ROH
|
TH |
|
Yunnan Chihong Zinc & Germanium Co Ltd
SSE:600497
|
CN |
|
Mic AG
XETRA:M3BK
|
DE |
|
C
|
Cashbuild Ltd
JSE:CSB
|
ZA |
|
L
|
Lagenda Properties Bhd
KLSE:LAGENDA
|
MY |
|
Vidrala SA
MAD:VID
|
ES |
|
C
|
Camsing Healthcare Ltd
SGX:BAC
|
SG |
|
SGT German Private Equity GmbH & Co KgaA
XETRA:GAI
|
DE |
|
Bigben Interactive SA
PAR:BIG
|
FR |
|
B
|
Bartronics India Ltd
NSE:ASMS
|
IN |
|
M
|
Minera Frisco SAB de CV
BMV:MFRISCOA-1
|
MX |
|
C
|
Concentra Group Holdings Parent Inc
NYSE:CON
|
US |
Kintara Therapeutics Inc
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.
